{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:58:15Z","timestamp":1760144295949,"version":"build-2065373602"},"reference-count":43,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Burkitt lymphoma (BL) accounts for 10\u201335% of AIDS-defining lymphoma in people with HIV (PWH). Previous research consisting of smaller cohorts has shown decreased survival for HIV-associated BL. This study aims to compare overall mortality in BL patients with and without HIV, while investigating impact of treatment modalities in HIV-associated BL. Methods: Using the 2004\u20132019 NCDB, we identified 4312 patients with stage 3 or 4 BL who had a known HIV status and received either chemotherapy alone or chemotherapy and immunotherapy. Time to death was evaluated using Kaplan\u2013Meier survival estimates. Risk of death was evaluated using an extended multivariable Cox model adjusted for multiple factors and with a Heaviside function for HIV status by time period (0\u20133 month vs. 3\u201360 month). Results: Of the 4312 patients included, 1514 (35%) had HIV. For months 0\u20133 from time of diagnosis, HIV status was not associated with a statistically significant increase in risk of death (HR = 1.04, 95% CI: 0.86, 1.26, p = 0.6648). From month 3to 60, positive HIV status was associated with a 55% increase in risk of death compared to those without HIV (95% CI: 1.38, 1.75, p &lt; 0.0001). Further, this difference in hazard rates (0\u20133 vs. 3\u201360) was statistically significant (HR = 1.49, 95% CI: 1.22\u20131.82, p &lt; 0.001). Conclusions: There is an increased mortality rate from months 3 to 60 in BL patients with HIV compared to patients without HIV. Additionally, risk of death in the first 3 months is significantly decreased by 45% in patients with HIV treated with combination chemotherapy and immunotherapy compared to patients without HIV receiving combination chemotherapy and immunotherapy, providing valuable clinical insight into treatment decision making in the care of HIV-associated BL.<\/jats:p>","DOI":"10.3390\/cancers16071397","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T09:36:54Z","timestamp":1712050614000},"page":"1397","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-Term Survival Rates and Treatment Trends of Burkitt Lymphoma in Patients with HIV\u2014A National Cancer Database (NCDB) Study"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0131-4636","authenticated-orcid":false,"given":"Clare M.","family":"Wieland","sequence":"first","affiliation":[{"name":"School of Medicine, Creighton University, Omaha, NE 68178, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3921-3473","authenticated-orcid":false,"given":"Ashley M.","family":"Tuin","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Omaha, NE 68178, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth J.","family":"Dort","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Omaha, NE 68178, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander G.","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Clinical Research & Public Health, School of Medicine, Creighton University, Omaha, NE 68178, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mridula","family":"Krishnan","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4045-3261","authenticated-orcid":false,"given":"Manasa","family":"Velagapudi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, School of Medicine, Creighton University, CHI Health, Omaha, NE 68124, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,2]]},"reference":[{"key":"ref_1","unstructured":"HIV Data and Statistics\u2014Global HIV Programme (2023, August 27). World Health Organization Web Site. Updated 2023. Available online: https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/strategic-information\/hiv-data-and-statistics."},{"key":"ref_2","unstructured":"HIV Basics\u2014Data and Trends: U.S. Statistics (2023, August 27). HIV.Gov Web Site. Updated 2022, Available online: https:\/\/www.hiv.gov\/hiv-basics\/overview\/data-and-trends\/statistics\/."},{"key":"ref_3","unstructured":"(2023, August 27). HIV Surveillance Report, 2021. Centers for Disease Control and Prevention. 2023. (Volume 34), Available online: http:\/\/www.cdc.gov\/hiv\/library\/reports\/hiv-surveillance.html."},{"key":"ref_4","unstructured":"HIV Treatment and Care (2024, March 18). Centers for Disease Control and Prevention. 26 September 2023, Available online: https:\/\/www.cdc.gov\/hiv\/clinicians\/treatment-care\/index.html#:~:text=Current%20treatment%20guidelines%20recommend%20antiretroviral,importance%20of%20adhering%20to%20ART."},{"key":"ref_5","unstructured":"HIV.Gov (2023, December 18). The Global HIV and AIDS Epidemic. HIV.Gov Web Site. Updated 2023, Available online: https:\/\/www.hiv.gov\/federal-response\/pepfar-global-aids\/global-hiv-aids-overview\/."},{"key":"ref_6","first-page":"1403","article-title":"A lymphomagenic role for HIV beyond immune suppression?","volume":"127","author":"Dolcetti","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000456036","article-title":"HIV-associated malignant lymphoma","volume":"40","author":"Brunnberg","year":"2017","journal-title":"Oncol. Res. Treat."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"507257","DOI":"10.1155\/2012\/507257","article-title":"HIV-associated Hodgkin\u2019s lymphoma: Prognosis and therapy in the era of cART","volume":"2012","author":"Jacobson","year":"2012","journal-title":"Adv. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3109\/10428194.2015.1055483","article-title":"HIV-associated lymphoma sub-type distribution, immunophenotypes and survival in an urban clinic population","volume":"57","author":"Riedel","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.semcancer.2013.08.004","article-title":"Lymphomas occurring specifically in HIV-infected patients: From pathogenesis to pathology","volume":"23","author":"Gloghini","year":"2013","journal-title":"Semin. Cancer Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1001\/jama.285.13.1736","article-title":"Association of cancer with AIDS-related immunosuppression in adults","volume":"285","author":"Frisch","year":"2001","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1056\/NEJM199904223401604","article-title":"Identification of common germinal-center B-cell precursors in two patients with both Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma","volume":"340","author":"Brauninger","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1002\/cncr.32158","article-title":"Advanced stage at diagnosis and elevated mortality among HIV-infected US cancer patients in the national cancer database","volume":"125","author":"Coghill","year":"2019","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/BLCTT.S361320","article-title":"HIV\/AIDS associated lymphoma: Review","volume":"12","author":"Berhan","year":"2022","journal-title":"Blood Lymphat. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e23853","DOI":"10.1097\/MD.0000000000023853","article-title":"Burkitt lymphoma associated with human immunodeficiency virus infection and pulmonary tuberculosis: A case report","volume":"99","author":"Birlutiu","year":"2020","journal-title":"Medicine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2352-3026(20)30126-5","article-title":"HIV-associated Burkitt lymphoma","volume":"7","author":"Murphy","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1097\/QAD.0b013e32833a0961","article-title":"Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy","volume":"24","author":"Chao","year":"2010","journal-title":"AIDS"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1158\/1055-9965.EPI-16-0595","article-title":"HIV infection and survival of lymphoma patients in the era of highly active antiretroviral therapy","volume":"26","author":"Han","year":"2017","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1158\/1055-9965.EPI-16-0273","article-title":"Contributions of HIV to non-Hodgkin lymphoma mortality trends in the United States","volume":"25","author":"Howlader","year":"2016","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1097\/QAD.0000000000003549","article-title":"Factors associated with survival in patients with lymphoma and HIV","volume":"37","author":"Vargas","year":"2023","journal-title":"AIDS"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1182\/bloodadvances.2021004458","article-title":"HIV-associated Burkitt lymphoma: Outcomes from a US-UK collaborative analysis","volume":"5","author":"Alderuccio","year":"2021","journal-title":"Blood Adv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1080\/10428194.2022.2027402","article-title":"Burkitt lymphoma\u2014No impact of HIV status on outcomes with rituximab-based chemoimmunotherapy","volume":"64","author":"Tan","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/annonc\/mdq677","article-title":"Evaluation of the addition of rituximab to CODOX-M\/IVAC for Burkitt\u2019s lymphoma: A retrospective analysis","volume":"22","author":"Barnes","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/S0140-6736(15)01317-3","article-title":"Rituximab and dose-dense chemotherapy for adults with Burkitt\u2019s lymphoma: A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Ribrag","year":"2016","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1080\/10428194.2017.1403597","article-title":"Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: A comparison within one prospective trial AMC034","volume":"59","author":"Tan","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_26","unstructured":"About The National Cancer Database (2023, July 21). American College of Surgeons. Available online: https:\/\/www.facs.org\/quality-programs\/cancer-programs\/national-cancer-database\/about\/."},{"key":"ref_27","unstructured":"North American Association of Central Cancer Registries (2023, July 21). Site Specific Data Items (SSDI)\/Grade\u2014Lymphoma. Available online: https:\/\/apps.naaccr.org\/ssdi\/schema\/lymphoma\/?breadcrumbs=(~schema_list~),(~view_schema~,~lymphoma~),(~view_naaccr_item~,~3859~)."},{"key":"ref_28","unstructured":"National Cancer Institute\u2014SEER Registrar Staging Assistant (2024, February 12). EOD Data\u2014NAACCR Item #3859: HIV Status. National Cancer Institute\u2014SEER Registrar Staging Assistant Web Site. Updated 2023, Available online: https:\/\/staging.seer.cancer.gov\/naaccr\/item\/eod_public\/3.0\/3859\/?breadcrumbs=(~view_schema~,~lymphoma_cll_sll~)."},{"key":"ref_29","unstructured":"Kanbar, A.H. (2023, August 31). Burkitt Lymphoma and Burkitt-Like Lymphoma Treatment & Management. Medscape Web Site. Updated 2022. Available online: https:\/\/emedicine.medscape.com\/article\/1447602-treatment#d9."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.jiac.2021.06.012","article-title":"Incidence and spectrum of infections among HIV\/AIDS patients with lymphoma during chemotherapy","volume":"27","author":"Wang","year":"2021","journal-title":"J. Infect. Chemother. Off. J. Jpn. Soc. Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/PPO.0000000000000448","article-title":"HIV Lymphoma and Burkitts Lymphoma","volume":"26","author":"Noy","year":"2020","journal-title":"Cancer J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e864","DOI":"10.1016\/j.clml.2020.06.003","article-title":"Outcomes of treatment for HIV-Infected Lymphoma patients: A National Cancer Database (NCDB) analysis","volume":"20","author":"Jayakrishnan","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/cid\/ciu174","article-title":"Management of HIV infection in patients with cancer receiving chemotherapy","volume":"59","author":"Torres","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2040620713514682","article-title":"Rituximab is associated with improved survival in Burkitt lymphoma: A retrospective analysis from two US academic medical centers","volume":"5","author":"Wildes","year":"2014","journal-title":"Ther. Adv. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/cncr.23522","article-title":"High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: Comparison of results in human immunodeficiency virus-infected and noninfected patients","volume":"113","author":"Oriol","year":"2008","journal-title":"Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood.V108.11.2736.2736","article-title":"Novel treatment of Burkitt lymphoma with dose-adjusted EPOCH-rituximab: Preliminary results showing excellent outcome","volume":"108","author":"Dunleavy","year":"2006","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00277-015-2501-1","article-title":"Effect of rituximab on adult Burkitt\u2019s lymphoma: A systematic review and meta-analysis","volume":"95","author":"Nie","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/bjh.15262","article-title":"Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M\/IVAC plus or minus rituximab","volume":"181","author":"Zhu","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1002\/cncr.26723","article-title":"Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma","volume":"118","author":"Barta","year":"2012","journal-title":"Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3 trial of chop with or without rituximab in patients with HIV-associated non-Hodgkin Lymphoma: AIDS-Malignancies Consortium Trial 010","volume":"106","author":"Kaplan","year":"2005","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1037\/a0032694","article-title":"A pandemic of the poor: Social disadvantage and the U.S. HIV epidemic","volume":"68","author":"Pellowski","year":"2013","journal-title":"Am. Psychol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/oem.2007.034363","article-title":"Disease severity, self-reported experience of workplace discrimination and employment loss during the course of chronic HIV disease: Differences according to gender and education","volume":"65","author":"Gueguen","year":"2008","journal-title":"Occup. Environ. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/7\/1397\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:22:22Z","timestamp":1760106142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/7\/1397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,2]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["cancers16071397"],"URL":"https:\/\/doi.org\/10.3390\/cancers16071397","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2024,4,2]]}}}